News
Kenvue outlook revised to negative by S&P amid strategic review
The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show net sales falling approximately 4%, worse than S&P’s expected 1% decline.
Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...
“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to ...
With the duration and frequency of cough episodes increasing among Indians since the onset of COVID-19, Kenvue, the world’s ...
3don MSN
All that culminated on Monday with the abrupt resignation of Kenvue CEO Thibaut Mongon, his replacement by board director ...
Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company ...
Benadryl maker Kenvue partners with the Association of Physicians of India to open Centres of Excellence for clinical ...
Barchart on MSN1d
Kenvue's Q2 2025 Earnings: What to ExpectKenvue is expected to release its second-quarter earnings next month, and analysts anticipate a double-digit profit dip.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback